Evaluation of NM108 on prevention of visual acuity loss and retinal inflammation and in a rat model of diabetes

Focus: 

To assess the effects of a novel drug on vision and inflammation in a model of diabetic macular edema (DME)

Anticipated Impact: 

More effective and less costly treatment for DME

Abstract: 

There are an estimated 746,000 individuals ages 40 or older in the US with diabetic macular edema (DME), which can cause progressive visual decline if untreated. Current DME therapies are costly and painful and do not fully address the inflammation that is the root cause of DME. In contrast, NM108, a new eye drop under development by NeuMedics, has potent anti-inflammatory activity and is anticipated to have a lower cost of goods. LSDF funding will support NM108 synthesis and assessment of the effects of varying doses on visual acuity and inflammation in a DME model. A successful outcome is expected to position NeuMedics for further preclinical and clinical testing required for regulatory approval.

Collaborating organizations: Echelon Biosciences, EyeCRO

Diabetic Macular Edema Treatment

Grant Update

Principal Investigator:
Iain Duncan
Grantee Organization:
NeuMedics, Inc.
Grant Title:
Evaluation of NM108 on prevention of visual acuity loss and retinal inflammation and in a rat model of diabetes
Grant Cohort and Year:
2015 Proof of Concept (03)
Grant Period:
02/01/2015 - 01/31/2017 (Completed)
Grant Amount:
$213,204
Inflammation inside the eye contributes to the loss of visual acuity experienced by diabetics and will eventually cause blindness if not properly treated. The eye reacts to the inflammation by producing new blood vessels (angiogenesis) also known as VEGF. Treatment today includes intravitreal injection of anti-VEGF drugs at least once per month for 12-18 months; it is 40% effective painful and expensive. Long term safety of frequent injections is not yet known. In its proof of concept study NeuMedics new compound successfully treated diabetic rats using a novel topical formulation and effectively shutdown the inflammation inside the eye. Shutting down the inflammation means that patients may no longer have to endure intravitreal injections to treat there macular edema or go through the pain and expense of this form of treatment. Importantly, the millions of diabetics outside the USA and Europe will now have a treatment option that was never before availble to them.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Diabetic Macular Edema Treatment